Abbott Laboratories (ABT)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
$113.60-1.65%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · ABT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks ABT against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 100% of the last 8 guided quarters · 15.3% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
• Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent 1 .
Stated in 4 of 8 supplied quarters. Management reported: “• Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent 1 .” “• Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5% 1 .” Revenue was $13.013 billion in 2026-Q3.
“• Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent 1 .”
“• Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5% 1 .”
“• Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% 1 .”
“• Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.”
• On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's port…
Stated in 2 of 8 supplied quarters. Management reported: “• On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's portfolio.” “• In November, Abbott announced an agreement to acquire Exact Sciences, a move that will position the company to enter and lead in the fast-growing cancer diagnostics market.”
• Abbott expanded its leadership in Electrophysiology with two significant regulatory approvals: • In December, Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt™ PFA Sys…
Stated in 1 of 8 supplied quarters. Management reported: “• Abbott expanded its leadership in Electrophysiology with two significant regulatory approvals: • In December, Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt™ PFA System, bringing Abbott's first pulsed field ablation (PFA) offering to patients in the United States.” “• In January, Abbott announced the company obtained CE Mark for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver radiofrequency (RF) and PFA energy to treat patients battling atrial fibrillation.”
• Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028.
Stated in 2 of 8 supplied quarters. Management reported: “• Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028.” “• Abbott's two new manufacturing and R&D investments in Illinois and Texas, totaling $0.5 billion, are projected to go live by the end of 2025.”
“• Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028.”
Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales.
Over the trailing year it converted 1.30x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.
“• On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's port…”
“• In November, Abbott announced an agreement to acquire Exact Sciences, a move that will position the company to enter and lead in the fast-growing cancer diagnostics market.”
“• Abbott expanded its leadership in Electrophysiology with two significant regulatory approvals: • In December, Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt™ PFA Sys…”
“• Abbott's two new manufacturing and R&D investments in Illinois and Texas, totaling $0.5 billion, are projected to go live by the end of 2025.”